Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey

---

Atıf İçin Kopyala

Ormeci N., Malhan S., BALIK İ., ERGÖR G., Razavi H., Robbins S.

HEPATOLOGY INTERNATIONAL, cilt.11, sa.6, ss.509-516, 2017 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 11 Sayı: 6
• Basım Tarihi: 2017
• Doi Numarası: 10.1007/s12072-017-9820-3
• Dergi Adı: HEPATOLOGY INTERNATIONAL
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.509-516
• Anahtar Kelimeler: HCV, Economic impact, Cost-effectiveness, Treatment, WHO Targets, GENOTYPE 1 INFECTION, UNITED-STATES, LIVER-DISEASE, RISK-FACTORS, HCV, SOFOSBUVIR, LEDIPASVIR, VIRUS, RIBAVIRIN, ABT-450/R-OMBITASVIR
• Ankara Üniversitesi Adresli: Evet

Özet

Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.